Investor Rights Law Firm Investigates Tourmaline Bio, CoreCard, PB Bankshares Mergers

Halper Sadeh LLC is investigating potential violations of federal securities laws and fiduciary duties in the following company sales: Tourmaline Bio's sale to Novartis for $48.00 per share, CoreCard Corporation's sale to Euronet, and PB Bankshares' sale to Norwood Financial Corp. Shareholders are advised to click the links provided to learn more about their rights and options.

Halper Sadeh LLC, an investor rights law firm, has announced that it is investigating potential violations of federal securities laws and fiduciary duties in the recent sales of Tourmaline Bio, CoreCard Corporation, and PB Bankshares. The firm is examining the transactions for shareholders' potential rights and options.

Tourmaline Bio, a late-stage biotechnology company, was acquired by Novartis AG for $48 per share, valuing the transaction at approximately $1.4 billion Novartis AG Buys Tourmaline Bio in $1.4B Deal^[1]. CoreCard Corporation was sold to Euronet for an exchange ratio between 0.2783 and 0.3142 of Euronet common stock per share of CoreCard SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates VECO, WOW, CCRD on Behalf of Shareholders^[2]. PB Bankshares' sale to Norwood Financial Corp. is also under scrutiny.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, or other relief and benefits on behalf of shareholders. The firm operates on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket payment of legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.

For more information, shareholders can visit the links provided for each company. Halper Sadeh LLC represents investors who have fallen victim to securities fraud and corporate misconduct, and has recovered millions of dollars on behalf of defrauded investors.